UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth

Cancer letters, 2018-03, Vol.417, p.182-191

2018

Link zum Volltext

Verfügbarkeit prüfen

Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7)

Cancer letters, 2017-07, Vol.398, p.62-69

2017

Link zum Volltext

Verfügbarkeit prüfen

Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment

Molecular cancer, 2016-01, Vol.15 (7), p.7-7, Article 7

2016

Link zum Volltext

Verfügbarkeit prüfen

D-2-Hydroxyglutarate in Glioma Biology

Cells (Basel, Switzerland), 2021-09, Vol.10 (9), p.2345

2021

Link zum Volltext

Verfügbarkeit prüfen

Genotoxic therapy and resistance mechanism in gliomas

Pharmacology & therapeutics (Oxford), 2021-12, Vol.228, p.107922-107922, Article 107922

2021

Link zum Volltext

Verfügbarkeit prüfen

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications

Biomedicines, 2020-08, Vol.8 (9), p.294

2020

Link zum Volltext

Verfügbarkeit prüfen

Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity

Journal of experimental & clinical cancer research, 2022-08, Vol.41 (1), p.1-235, Article 235

2022

Link zum Volltext

Verfügbarkeit prüfen

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer

Cell death & disease, 2020-11, Vol.11 (11), p.942-942, Article 942

2020

Link zum Volltext

Verfügbarkeit prüfen

ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling

Journal of experimental & clinical cancer research, 2021-01, Vol.40 (1), p.3-3, Article 3

2021

Link zum Volltext

Verfügbarkeit prüfen

Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity

Cancer letters, 2020-12, Vol.495, p.100-111

2020

Link zum Volltext

Verfügbarkeit prüfen

Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2

Clinical cancer research, 2023-04, Vol.29 (7), p.1305-1316

2023

Link zum Volltext

Verfügbarkeit prüfen

A nucleolus-predominant piggyBac transposase, NP-mPB, mediates elevated transposition efficiency in mammalian cells

PloS one, 2014-02, Vol.9 (2), p.e89396

2014

Link zum Volltext

Verfügbarkeit prüfen

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression

EBioMedicine, 2019-02, Vol.40, p.504-516

2019

Link zum Volltext

Verfügbarkeit prüfen

R26R-GR: a Cre-activable dual fluorescent protein reporter mouse

PloS one, 2012-09, Vol.7 (9), p.e46171-e46171

2012

Link zum Volltext

Verfügbarkeit prüfen

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells

Aging (Albany, NY.), 2020-09, Vol.12 (17), p.17694-17712

2020

Link zum Volltext

Verfügbarkeit prüfen

New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals

Oncotarget, 2016-10, Vol.7 (41), p.66769-66775

2016

Link zum Volltext

Verfügbarkeit prüfen

PD46-12 PRECLINICAL STUDIES USING CISPLATIN/CARBOPLATIN TO RESTORE THE ENZALUTAMIDE SENSITIVITY VIA DEGRADING THE ANDROGEN RECEPTOR SPLICING VARIANT 7 (ARV7) TO FURTHER SUPPRESS ENZALUTAMIDE RESISTANT PROSTATE CANCER

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression

Cancer letters, 2019-03, Vol.444, p.35-44

2019

Link zum Volltext

Verfügbarkeit prüfen

MP16-14 ERβ-MEDIATED ALTERATION OF CIRCATP2B1 AND MIR-204-3P SIGNALING PROMOTES INVASION OF CLEAR CELL RENAL CELL CARCINOMA

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Link zum Volltext

Verfügbarkeit prüfen

MP16-04 TARGETING NEWLY IDENTIFIED ERβ/TGF-β1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ERβ SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Link zum Volltext

Verfügbarkeit prüfen

The New Therapeutic Strategies for Improving the Efficacy and Reducing the Adverse Effects of Radiotherapy for Early Stage Prostate Cancer

Chou, Fu-Ju

2020

Link zum Volltext
ProQuest

MP87-13 ESTROGEN RECEPTOR α IN CANCER ASSOCIATED FIBROBLASTS SUPPRESSES PROSTATE CANCER INVASION VIA REDUCING CCL5, IL6 AND MACROPHAGE INFILTRATION IN THE TUMOR MICROENVIRONMENT

The Journal of urology, 2017-04, Vol.197 (4), p.e1170-e1171

2017

Link zum Volltext

Verfügbarkeit prüfen

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progressionResearch in context

EBioMedicine, 2019-02, Vol.40, p.504-516

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3495: A nucleolus-predominant piggyBac transposase increases transposition efficiency in human cancer cells

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3495-3495

2014

Link zum Volltext

Verfügbarkeit prüfen

Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer

Journal of cellular and molecular medicine, 2019-11, Vol.23 (11), p.7417-7426

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(31)
Dissertationen
(1)

Sprache

Englisch
(32)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth

Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7)

Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment

D-2-Hydroxyglutarate in Glioma Biology

Genotoxic therapy and resistance mechanism in gliomas

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications

Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer

ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling

Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity

Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2

A nucleolus-predominant piggyBac transposase, NP-mPB, mediates elevated transposition efficiency in mammalian cells

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression

R26R-GR: a Cre-activable dual fluorescent protein reporter mouse

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells

New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals

PD46-12 PRECLINICAL STUDIES USING CISPLATIN/CARBOPLATIN TO RESTORE THE ENZALUTAMIDE SENSITIVITY VIA DEGRADING THE ANDROGEN RECEPTOR SPLICING VARIANT 7 (ARV7) TO FURTHER SUPPRESS ENZALUTAMIDE RESISTANT PROSTATE CANCER

Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression

MP16-14 ERβ-MEDIATED ALTERATION OF CIRCATP2B1 AND MIR-204-3P SIGNALING PROMOTES INVASION OF CLEAR CELL RENAL CELL CARCINOMA

MP16-04 TARGETING NEWLY IDENTIFIED ERβ/TGF-β1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ERβ SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA

The New Therapeutic Strategies for Improving the Efficacy and Reducing the Adverse Effects of Radiotherapy for Early Stage Prostate Cancer

MP87-13 ESTROGEN RECEPTOR α IN CANCER ASSOCIATED FIBROBLASTS SUPPRESSES PROSTATE CANCER INVASION VIA REDUCING CCL5, IL6 AND MACROPHAGE INFILTRATION IN THE TUMOR MICROENVIRONMENT

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progressionResearch in context

Abstract 3495: A nucleolus-predominant piggyBac transposase increases transposition efficiency in human cancer cells

Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer

Suchergebnisse filtern